Advertisement
Advertisement
INCY
Incyte Genomics Inc
97.08
USDSponsored
+1.48
+1.55%
May 20, 16:00 UTC -4
Closed
After-Market
96.00
-1.08
-1.11%
INCY Earnings Reports
Positive Surprise Ratio
INCY beat 21 of 41 last estimates.
51%
Next Report
Date of Next Report
Jul 27, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.40B
/$1.86
Implied change from Q1 26 (Revenue/ EPS)
+9.66%
/+2.76%
Implied change from Q2 25 (Revenue/ EPS)
+14.81%
/+18.47%
Incyte Genomics Inc earnings per share and revenue
On Apr 28, 2026, INCY reported earnings of 1.81 USD per share (EPS) for Q1 26, beating the estimate of 1.39 USD, resulting in a 29.43% surprise. Revenue reached 1.27 billion, compared to an expected 1.24 billion, with a 2.90% difference. The market reacted with a +1.13% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of 1.86 USD, with revenue projected to reach 1.40 billion USD, implying an increase of 2.76% EPS, and increase of 9.66% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Immuneering Corporation Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.29%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.04
Surprise
+12.85%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
Citius Oncology, Inc. Common Stock
Report Date
May 15, 2026 For Q2 26
Estimate
-$0.01
Actual
-$1.43
Surprise
-13919.61%
Rein Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.19
Surprise
+61.98%
CervoMed Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.79
Actual
-$0.86
Surprise
-8.09%
Neuphoria Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.09
Surprise
+90.90%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Incyte Genomics Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Incyte Genomics Inc reported EPS of $1.81, beating estimates by 29.43%, and revenue of $1.27B, 2.9% above expectations.
How did the market react to Incyte Genomics Inc's Q1 2026 earnings?
The stock price moved up 1.13%, changed from $94.65 before the earnings release to $95.72 the day after.
When is Incyte Genomics Inc expected to report next?
The next earning report is scheduled for Jul 27, 2026.
What are the forecasts for Incyte Genomics Inc's next earnings report?
Based on 12
analysts, Incyte Genomics Inc is expected to report EPS of $1.86 and revenue of $1.40B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement